In-vivo activity and enzymatic hydrolysis of novel prostaglandin F2 alpha prodrugs in ocular tissues.
Enzymatic hydrolysis and in-vivo ocular studies were performed on a novel series of prostaglandin F2 alpha (PGF2 alpha) pivaloyl ester prodrugs to assess their therapeutic potential. These novel PGF2 prodrugs were esterified at the 9-, 11-, and 15-OH positions. Their enzymatic hydrolysis rates were compared to PGF2 alpha 1-isopropyl ester in dog, monkey, and human ocular tissues. Intraocular pressure (IOP) studies were performed in monkeys and dogs, and ocular surface hyperemia was monitored in dogs. PGF2 alpha 9-monopivaloyl ester was not enzymatically hydrolysed in dog and human ocular tissues. PGF2 alpha 11- and 15-monopivaloyl esters and PGF2 alpha 11,15-dipivaloyl ester were converted to PGF2 alpha by all ocular tissues at a substantially slower rate than PGF2 alpha l-isopropyl ester. Despite their slow enzymatic hydrolysis rates, the ocular hypotensive activity of PGF2 alpha mono and dipivaloyl esters, where positions 11- and 15- were functionalized, closely approached the activity achieved with PGF2 alpha l-isopropyl ester. The degree of ocular surface hyperemia associated with PGF2 alpha 11-pivaloyl ester and PGF2 alpha 11,15-dipivaloyl ester was less than that associated with equivalent doses of PGF2 alpha l-isopropyl ester. It appears that rapid enzymatic hydrolysis rates are not necessary to obtain efficacious ocular hypotensive PGF2 alpha ester prodrugs. Slow enzymatic hydrolysis rates may assist in reducing the degree of ocular surface hyperemia. A further contributory factor in this regard could be the approximately ten-fold favorable difference in enzymatic hydrolysis rates between iris-ciliary body and conjunctival tissue for these novel pivaloyl esters of PGF2 alpha. These factors appear to translate into an improved therapeutic index for separating ocular hypotensive and ocular surface hyperemic effects.
Woodward
D F
DF
Department of Biological Sciences, Allergan, Inc., Irvine, CA 92715, USA.
Chan
M F
MF
Cheng-Bennett
A
A
Wheeler
L A
LA
Chen
G
G
Burke
J A
JA
Kharlamb
A
A
Lai
R K
RK
Shan
T
T
D000818:Animals; D000959:Antihypertensive Agents / Q000378:metabolism / Q000494:pharmacology*; D002924:Ciliary Body / Q000378:metabolism; D003228:Conjunctiva / Q000378:metabolism; D003315:Cornea / Q000378:metabolism; D046508:Culture Techniques; D015237:Dinoprost / Q000378:metabolism / Q000494:pharmacology*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004952:Esters; D005123:Eye / Q000187:drug effects* / Q000378:metabolism; D005260:Female; D006801:Humans; D006868:Hydrolysis; D006940:Hyperemia / Q000139:chemically induced; D007429:Intraocular Pressure / Q000187:drug effects*; D007498:Iris / Q000378:metabolism; D008252:Macaca fascicularis; D008297:Male; D011355:Prodrugs / Q000378:metabolism / Q000494:pharmacology*; D011680:Pupil / Q000187:drug effects
D000959:Antihypertensive Agents; D004952:Esters; D011355:Prodrugs; D015237:Dinoprost